12:00 London, 14:00 Helsinki, 11 April 2014 - Afarak Group Plc, Stock Exchange Release INVITATION TO THE ANNUAL GENERAL MEETING The shareholders of Afarak Group Plc are invited to attend the Annual General Meeting to be held on 8 May 2014, starting at 10:00 a.m. (Finnish time) in Helsinki at Restaurant Palace at the address: Eteläranta 10, 00130 Helsinki, Finland. The registration of the participants begins at 9:30 a.m. A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING: 1. Opening of the meeting 2. Election of the chairman and election of the secretary 3. Approval of the agenda 4. Election of the scrutinizer of the minutes and the person to supervise the counting of votes 5. Recording the legality and quorum of the meeting 6. Adoption of the list of votes 7. Review by the CEO 8. Presentation of the financial statements for the year 2013 and the report of the Board of Directors 9. Presentation of the auditor's report 10. Adoption of the financial statements and the group financial statements 11. Resolution on the use of the profit and the capital redemption It is proposed to the Annual General Meeting that the company shall not pay a dividend in respect of the financial year ended on 31 December, 2013. The Board of Directors proposes to the Annual General Meeting a capital redemption of EUR 0.02 per share for the year ended on 31 December 2013. The payment is proposed to be made from the company's fund for invested unrestricted equity. The capital redemption is repaid to the shareholders who are registered on the company's shareholder register maintained by Euroclear Finland Ltd on the record date for payment, being 13 May 2014. Shares will commence trading without the right to the capital redemption payment on 9 May 2014 in London and Helsinki. The Board of Directors proposes to the Annual General Meeting that the capital redemption shall be paid by the Company on 22 May 2014. 12. Resolution on the discharge of the members of the Board of Directors and the CEO from liability 13. Resolution on the remuneration of the members of the Board of Directors and of the Auditor It is proposed to the Annual General Meeting that all Board Members would be paid EUR 3,000 per month. Furthermore, the non-executive Board Members who serve on the Board's Committees shall be paid additional EUR 1,500 per month for the committee work. The executive Board members shall not be paid remuneration for their work on the Board of Directors. The Board of Directors proposes to the Annual General Meeting that the company will pay the fee to the auditor against an invoice that is reviewed and approved by the company. 14. Resolution on the number of the members of the Board of Directors It is proposed to the Annual General Meeting that the number of members of the Board of Directors shall be six. 15. Election of the members of the Board of Directors It is proposed to the Annual General Meeting that Mr Michael Lillja (Finnish citizen), Mr Markku Kankaala (Finnish citizen), Dr Danko Koncar (Croatian citizen), Dr Jelena Manojlovic (UK citizen), Dr Alfredo Parodi (Italian citizen) and Ms Bernice Smart (UK citizen) will be re-elected for the next mandate that begins from the end of the General Meeting and ends at the end of the Annual General Meeting on 2015. 16. Election of the Auditor The Board of Directors proposes to the Annual General Meeting according to the recommendation by the company's Audit Committee that Authorized Public Accountant Firm Ernst & Young Oy would be re-elected as the auditor of the company. Ernst & Young Oy has proposed that the auditor with the main responsibility would be APA Erkka Talvinko. 17. Authorizing the Board of Directors to decide upon share issue and upon issuing other special rights that entitle to shares The Board of Directors proposes to the Annual General Meeting that the Board of Directors be authorized to issue ordinary shares and issue stock options and other special rights that entitle to shares. By virtue of the authorization shares could be issued in one or more tranches up to a maximum of 24,843,200 new shares or shares owned by the company. This equates approximately 10 % of the company's current registered shares. The Board of Directors would, by virtue of the authorization, be entitled to decide on the share issues and on the issuing of stock options and other special rights that entitle to shares. The Board of Directors may use the authorization among other things to raise additional finance and enabling corporate and business acquisitions or other arrangements and investments of business activity or for employee incentive and commitment schemes. The Board of Directors proposes that, by virtue of the authorization, the Board of Directors can decide both on share issue against payment and on share issue without payment. The payment of the subscription price could also be made with other consideration than money. The authorization would contain right to decide on derogating from shareholders' pre-emptive right to share subscription provided that the conditions set in the Companies' Act are fulfilled. The Board of Directors proposes that the authorization replaces all previous authorizations and that it is valid two (2) years as from the decision of the General Meeting. 18. Authorizing the Board of Directors to decide on the acquiring of own shares The Board of Directors proposes to the Annual General Meeting that the Board of Directors would be authorized to decide on the acquiring of company's own shares. By virtue of the authorization concerning the acquiring of own shares a maximum of 15,000,000 own shares could be acquired with the funds from the company's unrestricted shareholders' equity, however, in such a way that the total number of own shares, which the Company and its subsidiaries have in their possession or as a pledge, does not exceed one tenth of all shares in accordance with Section 11 of Chapter 15 of the Finnish Companies Act. The authorization covers acquisition of shares in public trade in NASDAQ OMX Helsinki Oy and also outside of the public trade. The compensation paid for acquired shares shall be based on the market value. Derivative contracts, share loan agreements or other agreements may be made within laws and regulations if they are customary to capital market. The authorization entitles the board of directors to make a resolution on acquisition otherwise than in the relation of the shares owned by the shareholders (directed acquisition) according the preconditions set forth in the Companies Act. The Board of Directors proposes that the authorization concerning the acquisition of own shares would among other things be used in developing the company's capital structure, in financing and executing corporate acquisitions and other arrangements, in executing the company's share-based incentive systems or otherwise in being transferred or cancelled. The acquisition of shares reduces the company's distributable non-restricted shareholders' equity. The Board of Directors proposes that the authorization replaces all previous authorizations and that it is valid 18 months as from the decision of the General Meeting. 19. Closing of the Meeting B. DOCUMENTS OF THE GENERAL MEETING The Financial statements, proposals of the Board of Directors presented to the Annual General Meeting and all other documents will be kept on view in accordance with the Finnish Companies Act are available for the shareholders' inspection at least for three weeks preceding the Annual General Meeting at the company headquarters at the address: Kasarmikatu 36, 00130 Helsinki. In addition, the documents will be available for at least 21 days preceding the Annual General Meeting on the company's website at the address www.afarakgroup.com. Copies of these documents will be sent to shareholders on request. The minutes of the Meeting will be available on the above mentioned website at the latest from 22 May 2014. C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE ANNUAL GENERAL MEETING 1. Right to attend A shareholder who no later than on 25 April 2014 is registered as the Company's shareholder in a shareholder register held by Euroclear Finland Ltd has the right to participate in the Annual General Meeting. A shareholder whose shares are registered on his/her personal Finnish book-entry account is registered in the Company's shareholder register. 2. Notice to attend A shareholder wishing to attend the meeting shall give notice to attend the meeting to the Company no later than by 4:00 p.m. Helsinki time on 5 May 2014, either: - by letter to Afarak Group Plc, Kasarmikatu 36, 00130 Helsinki; - by e-mail to ilmo@afarakgroup.com; or - by fax to +358 9 412 9811. The notice shall be at the company before the deadline of the notice to attend. A shareholder is requested in addition to name to inform also his/her identity number or business ID, address, phone number and a name of possible representative. The personal data of shareholders shall be used only for purposes related to the general meeting and necessary registration related to that. Shareholders attending the general meeting have a right to request information concerning matters which are dealt with by the meeting as stated in the Finnish Companies Act, chapter 5, section 25. 3. Using representative and proxies A shareholder has a right to attend the meeting and use his rights via representative. A representative must present a dated proxy or must otherwise, in a reliable way, prove that he has a right to represent a shareholder. The Company does not have a proxy template available for shareholders. If a shareholder participates in the Annual General Meeting by means of several proxy representatives representing the shareholder with shares on different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration. Possible proxies are asked to be delivered in original form together with the notice to attend to address Afarak Group Plc, Kasarmikatu 36, 00130 Helsinki before the end of notice period 5 May 2014 at 4:00 p.m. Helsinki time. 4. Holders of nominee registered shares A holder of nominee registered shares is advised to request in good time in advance necessary instructions regarding the registration in the Company's shareholder register, issuing of proxy documents and registration for the Annual General Meeting from his/her custodian bank. The account management organization of the custodian bank will register a holder of nominee registered shares, who wants to participate in the Annual General Meeting, to be entered into the Company's temporary shareholder register no later than by 5 May 2014 at 10.00 a.m. Helsinki time. 5. Other instructions and information Afarak Group Plc has at the date of invitation, 11 April 2014, in total 248,432,000 shares in issue and of which 248,432,000 have voting rights. The company holds in total 4,244,717 shares in treasury. Afarak Group Plc has published the Report by the Board of Directors, the Financial Statements 2013, the Auditor's Report, the Corporate Governance Statement and the Remuneration Report in English and in Finnish. Shareholders may order the documents by phone from number +358 50 372 1130 on weekdays between 10:00 a.m. and 4:00 p.m. Helsinki time. The documents can also be found from the company website from address www.afarakgroup.com. IN HELSINKI, ON 11 April 2014 AFARAK GROUP PLC BOARD OF DIRECTORS This document is based on a translation into English of a document written in Finnish. In case of any discrepancies, inconsistencies or inaccuracies, the Finnish version shall prevail. For additional information, please contact: Afarak Group Plc Danko Koncar, CEO, +44 (0)20 7376 1175, danko.konchar@afarak.com Investec Bank Plc Jeremy Wrathall, +44 (0)20 7597 5970 Afarak Group is a chrome mining and minerals producer focused on delivering sustainable growth with a speciality alloys business in southern Europe and a ferro alloys business in southern Africa. The Company is listed on NASDAQ OMX Helsinki (AFAGR) and the Main Market of the London Stock Exchange (AFRK). www.afarakgroup.com Distribution: NASDAQ OMX Helsinki London Stock Exchange main media www.afarakgroup.com [HUG#1776685]
INVITATION TO THE ANNUAL GENERAL MEETING 12:00 London,
Top 10 Most Recent News Articles
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment
Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...
Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026
Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...
Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
Novo's Semaglutide Shows Promise in MASH Study
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth
AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...
Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings
The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...
Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar
A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...
Continue ReadingTop 5 Most Recently Viewed Articles
VivoPower Innovates with XRP-Focused Treasury Strategy
VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...
Continue Reading
Recognizing Excellence in Product Stewardship for 2024
Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...
Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty
Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...
Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair
Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...
Continue Reading
William James Wartinbee III Executes Significant Sell Strategy
William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...
Continue Reading